A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint

Science Signaling

Volumn 8, Issue 377, 2015, Pages ra48-

  Loureiro, Cláudia A ^a,b   Matos, Ana Margarida ^a,b   Dias Alves, Ångela ^a,b   Pereira, Joana F ^a,b   Uliyakina, Inna ^b   Barros, Patrícia ^a,b   Amaral, Margarida D ^b   Matos, Paulo ^a,b  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EZRIN; RAC1 PROTEIN; SCAFFOLD PROTEIN; UBIQUITIN PROTEIN LIGASE E3; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; CYTOSKELETON PROTEIN; LUMACAFTOR; PHOSPHOPROTEIN; RAC1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR; STUB1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL CYCLE CHECKPOINT; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; ANALYSIS OF VARIANCE; BIOTINYLATION; CELL LINE; CONFOCAL MICROSCOPY; CYSTIC FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE DELETION; GENETICS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; PROTEIN TRANSPORT; TEMPERATURE;

AMINOPYRIDINES; ANALYSIS OF VARIANCE; BENZODIOXOLES; BIOTINYLATION; CELL LINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOSKELETAL PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; PHOSPHOPROTEINS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN TRANSPORT; RAC1 GTP-BINDING PROTEIN; SEQUENCE DELETION; SODIUM-HYDROGEN ANTIPORTER; TEMPERATURE; UBIQUITIN-PROTEIN LIGASES;

EID: 84929667112     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaa1580     Document Type: Article

References (44)

1. T. K. Chaudhuri, S. Paul, Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 273, 1331-1349 (2006).
2. P. M. Conn, A. Ulloa-Aguirre, Pharmacological chaperones for misfolded gonadotropinreleasing hormone receptors. Adv. Pharmacol. 62, 109-141 (2011).
3. C. M. Farinha, P. Matos, M. D. Amaral, Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: Not just from the endoplasmic reticulum to the Golgi. FEBS J. 280, 4396-4406 (2013).
4. S. C. Bell, K. De Boeck, M. D. Amaral, New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol. Ther. 145, 19-34 (2015).
5. J. P. Clancy, S. M. Rowe, F. J. Accurso, M. L. Aitken, R. S. Amin, M. A. Ashlock, M. Ballmann, M. P. Boyle, I. Bronsveld, P. W. Campbell, K. De Boeck, S. H. Donaldson, H. L. Dorkin, J. M. Dunitz, P. R. Durie, M. Jain, A. Leonard, K. S. McCoy, R. B. Moss, J. M. Pilewski, D. B. Rosenbluth, R. C. Rubenstein, M. S. Schechter, M. Botfield, C. L. Ordoñez, G. T. Spencer-Green, L. Vernillet, S. Wisseh, K. Yen, M. W. Konstan, Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18 (2012).
6. Press Release, Two 24-week phase 3 studies of lumacaftor in combination with ivacaftor met primary endpoint with statistically significant improvements in lung function (FEV1) in people with cystic fibrosis who have two copies of the F508del mutation (2014); http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185.
7. J. R. Riordan, CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701-726 (2008).
8. F. Van Goor, S. Hadida, P. D. Grootenhuis, B. Burton, D. Cao, T. Neuberger, A. Turnbull, A. Singh, J. Joubran, A. Hazlewood, J. Zhou, J. McCartney, V. Arumugam, C. Decker, J. Yang, C. Young, E. R. Olson, J. J. Wine, R. A. Frizzell, M. Ashlock, P. Negulescu, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U.S.A. 106, 18825-18830 (2009).
9. F. Van Goor, H. Yu, B. Burton, B. J. Hoffman, Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13, 29-36 (2014).
10. S. Moniz, M. Sousa, B. J. Moraes, A. I. Mendes, M. Palma, C. Barreto, J. I. Fragata, M. D. Amaral, P. Matos, HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem. Biol. 8, 432-442 (2013).
11. C. M. Farinha, J. King-Underwood, M. Sousa, A. R. Correia, B. J. Henriques,M. Roxo-Rosa, A. C. Da Paula, J. Williams, S. Hirst, C. M. Gomes, M. D. Amaral, Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 20, 943-955 (2013).
12. T. Okiyoneda, H. Barrière, M. Bagdány, W. M. Rabeh, K. Du, J. Höhfeld, J. C. Young, G. L. Lukacs, Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805-810 (2010).
13. M. Sharma, F. Pampinella, C. Nemes, M. Benharouga, J. So, K. Du, K. G. Bache, B. Papsin, N. Zerangue, H. Stenmark, G. L. Lukacs, Misfolding diverts CFTR from recycling to degradation: Quality control at early endosomes. J. Cell Biol. 164, 923-933 (2004).
14. P. M. Apaja, H. Xu, G. L. Lukacs, Quality control for unfolded proteins at the plasma membrane. J. Cell Biol. 191, 553-570 (2010).
15. A. Hall, Rho family GTPases. Biochem. Soc. Trans. 40, 1378-1382 (2012).
16. T. Nakamura, K. Sakai, K. Matsumoto, Hepatocyte growth factor twenty years on: Much more than a growth factor. J. Gastroenterol. Hepatol. 26 (Suppl. 1), 188-202 (2011).
17. R. A. M. Panganiban, R. M. Day, Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol. Sin. 32, 12-20 (2011).
18. A. A. Birukova, N. Moldobaeva, J. Xing, K. G. Birukov, Magnitude-dependent effects of cyclic stretch on HGF- and VEGF-induced pulmonary endothelial remodeling and barrier regulation. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L612-L623 (2008).
19. A. A. Birukova, E. Alekseeva, A. Mikaelyan, K. G. Birukov, HGF attenuates thrombininduced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. FASEB J. 21, 2776-2786 (2007).
20. P. M. Haggie, J. K. Kim, G. L. Lukacs, A. S. Verkman, Tracking of quantum dot-labeled CFTR shows near immobilization by C-terminal PDZ interactions. Mol. Biol. Cell 17, 4937-4945 (2006).
21. J. Li, Z. Dai, D. Jana, D. J. Callaway, Z. Bu, Ezrin controls the macromolecular complexes formed between an adapter protein Na+/H+ exchanger regulatory factor and the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 280, 37634-37643 (2005).
22. E. C. Smyth, F. Sclafani, D. Cunningham, Emerging molecular targets in oncology: Clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther. 7, 1001-1014 (2014).
23. J. C. Stam, E. E. Sander, F. Michiels, F. N. van Leeuwen, H. E. Kain, R. A. van der Kammen, J. G. Collard, Targeting of Tiam1 to the plasma membrane requires the cooperative function of the N-terminal pleckstrin homology domain and an adjacent protein interaction domain. J. Biol. Chem. 272, 28447-28454 (1997).
24. K. R. Hallows, A. C. Fitch, C. A. Richardson, P. R. Reynolds, J. P. Clancy, P. C. Dagher, L. A. Witters, J. K. Kolls, J. M. Pilewski, Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. J. Biol. Chem. 281, 4231-4241 (2006).
25. G. M. Denning, M. P. Anderson, J. F. Amara, J. Marshall, A. E. Smith, M. J.Welsh, Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764 (1992).
26. J.Almaça,S.Dahimène, N.Appel,C.Conrad,K.Kunzelmann, R.Pepperkok,M. D.Amaral, Functional genomics assays to study CFTR traffic and ENaC function. Methods Mol. Biol. 742, 249-264 (2011).
27. A. Swiatecka-Urban, M. Duhaime, B. Coutermarsh, K. H. Karlson, J. Collawn, M. Milewski, G. R. Cutting, W. B. Guggino, G. Langford, B. A. Stanton, PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 277, 40099-40105 (2002).
28. L. Guerra, T. Fanelli, M. Favia, S. M. Riccardi, G. Busco, R. A. Cardone, S. Carrabino, E. J. Weinman, S. J. Reshkin, M. Conese, V. Casavola, Na+/H+ exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o- cells and rescues DF508 CFTR functional expression in cystic fibrosis cells. J. Biol. Chem. 280, 40925-40933 (2005).
29. F. C. Morales, Y. Takahashi, S. Momin, H. Adams, X. Chen, M.-M. Georgescu, NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol. Cell. Biol. 27, 2527-2537 (2007).
30. C. M. Farinha, M. Sousa, S. Canato, A. Schmidt, I. Uliyakina, and M. D. Amaral, Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR, Pharmacol. Res. Perspect., in press.
31. P. R. Cushing, A. Fellows, D. Villone, P. Boisguérin, D. R. Madden, The relative binding affinities of PDZ partners for CFTR: A biochemical basis for efficient endocytic recycling. Biochemistry 47, 10084-10098 (2008).
32. K. Arora, C. Moon, W. Zhang, S. Yarlagadda, H. Penmatsa, A. Ren, C. Sinha, A. P. Naren, Stabilizing rescued surface-localized DF508 CFTR by potentiation of its interaction with Na+/H+ exchanger regulatory factor 1. Biochemistry 53, 4169-4179 (2014).
33. L. J. Galietta, P. M. Haggie, A. S. Verkman, Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett. 499, 220-224 (2001).
34. H. Yang, A. A. Shelat, R. K. Guy, V. S. Gopinath, T. Ma, K. Du, G. L. Lukacs, A. Taddei, C. Folli, N. Pedemonte, L. J. V. Galietta, A. S. Verkman, Nanomolar affinity small molecule correctors of defective DF508-CFTR chloride channel gating. J. Biol. Chem. 278, 35079-35085 (2003).
35. A. Caputo, A. Hinzpeter, E. Caci, N. Pedemonte, N. Arous, M. Di Duca, O. Zegarra-Moran, P. Fanen, L. J. V. Galietta, Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. J. Pharmacol. Exp. Ther. 330, 783-791 (2009).
36. C. M. Farinha, P. Nogueira, F. Mendes, D. Penque, M. D. Amaral, The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem. J. 366, 797-806 (2002).
37. A. Saxena,Y.K.Banasavadi-Siddegowda,Y. Fan,S.Bhattacharya,G.Roy,D.R.Giovannucci, R. A. Frizzell, X. Wang, Human heat shock protein 105/110 kDa (Hsp105/110) regulates biogenesis and quality control ofmisfolded cystic fibrosis transmembrane conductance regulator at multiple levels. J. Biol. Chem. 287, 19158-19170 (2012).
38. L. He, P. Kota, A. A. Aleksandrov, L. Cui, T. Jensen, N. V. Dokholyan, J. R. Riordan, Correctors of DF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 27, 536-545 (2013).
39. P. D.W. Eckford, M. Ramjeesingh, S. Molinski, S. Pasyk, J. F. Dekkers, C. Li, S. Ahmadi, W. Ip, T. E. Chung, K. Du, H. Yeger, J. Beekman, T. Gonska, C. E. Bear, VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem. Biol. 21, 666-678 (2014).
40. E. M. Bradford, M. A. Sartor, L. R. Gawenis, L. L. Clarke, G. E. Shull, Reduced NHE3- mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G886-G898 (2009).
41. F. Bossard, E. Silantieff, E. Lavazais-Blancou, A. Robay, C. Sagan, B. Rozec, C. Gauthier, b1, b2, and b3 adrenoceptors and Na+/H+ exchanger regulatory factor 1 expression in human bronchi and their modifications in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 44, 91-98 (2011).
42. M.-M. Georgescu, F. C. Morales, J. R. Molina, Y. Hayashi, Roles of NHERF1/EBP50 in cancer. Curr. Mol. Med. 8, 459-468 (2008).
43. H. M. Botelho, I. Uliyakina, N. T. Awatade, M. C. Proença, C. Tischer, L. Sirianant, K. Kunzelmann, R. Pepperkok, M. D. Amaral, Protein traffic disorders: An effective high-throughput fluorescence microscopy pipeline for drug discovery. Sci. Rep. 5, 9038 (2015).
44. P. Matos, C. Oliveira, S. Velho, V. Gonçalves, L. T. da Costa, M. P. Moyer, R. Seruca, P. Jordan, B-RafV600E cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 135, 899-906 (2008).